F L Luan1, M Samaniego, M Kommareddi, J M Park, A O Ojo. 1. Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan, USA. fluan@med.umich.edu
Abstract
BACKGROUND: Late occurrence of cytomegalovirus (CMV) infection remains a concern in CMV-seronegative kidney and/or pancreas transplant recipients of CMV-seropositive organs (donor positive/recipient negative, D+/R-) despite the use of prophylaxis. We investigated the impact of various antibody induction regimens on CMV infection in this group of patients. METHODS: A total of 254 consecutive D+/R- kidney and/or pancreas transplant patients were studied. The induction agents rabbit anti-thymocyte globulin (rATG) or basiliximab were used according to the center practice. All patients received prophylaxis with valganciclovir (VGCV) for either 3 or 6 months. The occurrence of CMV infection was confirmed by positive DNA viremia. Multivariate Cox regression analyses were performed to determine risk factors for CMV infection. RESULTS: The cumulative incidence of CMV infection was 58, 112, and 59 cases per 1000 patient-years for patients who received no antibody induction, induction with rATG, or basiliximab induction, respectively (P=0.02). The use of rATG but not basiliximab was associated with an increased risk for CMV infection (adjusted hazard ratio [AHR] 2.13, 95% confidence interval [CI] 1.24-3.54, P=0.006). Acute rejection and its treatment with rATG were not associated with an increased risk for CMV infection when an additional course of VGCV was given following the treatment. Longer duration of prophylaxis was associated with a reduced risk for CMV infection (AHR 0.54, 95% CI 0.33-0.87, P=0.011). CONCLUSIONS: Induction with rATG is associated with increased risk of CMV infection. Longer duration of prophylaxis is beneficial.
BACKGROUND: Late occurrence of cytomegalovirus (CMV) infection remains a concern in CMV-seronegative kidney and/or pancreas transplant recipients of CMV-seropositive organs (donor positive/recipient negative, D+/R-) despite the use of prophylaxis. We investigated the impact of various antibody induction regimens on CMV infection in this group of patients. METHODS: A total of 254 consecutive D+/R- kidney and/or pancreas transplant patients were studied. The induction agents rabbit anti-thymocyte globulin (rATG) or basiliximab were used according to the center practice. All patients received prophylaxis with valganciclovir (VGCV) for either 3 or 6 months. The occurrence of CMV infection was confirmed by positive DNA viremia. Multivariate Cox regression analyses were performed to determine risk factors for CMV infection. RESULTS: The cumulative incidence of CMV infection was 58, 112, and 59 cases per 1000 patient-years for patients who received no antibody induction, induction with rATG, or basiliximab induction, respectively (P=0.02). The use of rATG but not basiliximab was associated with an increased risk for CMV infection (adjusted hazard ratio [AHR] 2.13, 95% confidence interval [CI] 1.24-3.54, P=0.006). Acute rejection and its treatment with rATG were not associated with an increased risk for CMV infection when an additional course of VGCV was given following the treatment. Longer duration of prophylaxis was associated with a reduced risk for CMV infection (AHR 0.54, 95% CI 0.33-0.87, P=0.011). CONCLUSIONS: Induction with rATG is associated with increased risk of CMV infection. Longer duration of prophylaxis is beneficial.
Authors: X Préville; M Flacher; B LeMauff; S Beauchard; P Davelu; J Tiollier; J P Revillard Journal: Transplantation Date: 2001-02-15 Impact factor: 4.939
Authors: R R Razonable; A Rivero; A Rodriguez; J Wilson; J Daniels; G Jenkins; T Larson; W C Hellinger; J R Spivey; C V Paya Journal: J Infect Dis Date: 2001-10-23 Impact factor: 5.226
Authors: G Mourad; V Garrigue; J P Squifflet; T Besse; F Berthoux; E Alamartine; D Durand; L Rostaing; P Lang; C Baron; D Glotz; C Antoine; P Vialtel; T Romanet; Y Lebranchu; A Al Najjar; C Hiesse; L Potaux; P Merville; J L Touraine; N Lefrancois; M Kessler; E Renoult; C Pouteil-Noble; R Cahen; C Legendre; J Bedrossian; P Le Pogamp; J Rivalan; M Olmer; R Purgus; F Mignon; B Viron; B Charpentier Journal: Transplantation Date: 2001-09-27 Impact factor: 4.939
Authors: Kevin C Abbott; Iman O Hypolite; Rebecca Viola; Ronald K Poropatich; Paul Hshieh; David Cruess; Clifton A Hawkes; Lawrence Y Agodoa Journal: Ann Epidemiol Date: 2002-08 Impact factor: 3.797
Authors: Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Yvon Lebranchu; Frank Bridoux; Matthias Büchler; Yannick Le Meur; Isabelle Etienne; Olivier Toupance; Bruno Hurault de Ligny; Guy Touchard; Bruno Moulin; Patrick Le Pogamp; Olivier Reigneau; Michel Guignard; Gérard Rifle Journal: Am J Transplant Date: 2002-01 Impact factor: 8.086
Authors: Joseph G Lawen; Elizabeth A Davies; Georges Mourad; Frederic Oppenheimer; Miguel Gonzalez Molina; Lionel Rostaing; Alan H Wilkinson; Laura L Mulloy; Bernard J Bourbigot; Hans Prestele; Alexander Korn; Danièle Girault Journal: Transplantation Date: 2003-01-15 Impact factor: 4.939
Authors: A A Boudreault; H Xie; R M Rakita; J D Scott; C L Davis; M Boeckh; A P Limaye Journal: Transpl Infect Dis Date: 2011-03-17 Impact factor: 2.228
Authors: Carlos A Q Santos; Daniel C Brennan; Mohammed J Saeed; Victoria J Fraser; Margaret A Olsen Journal: Clin Transplant Date: 2016-03-04 Impact factor: 2.863
Authors: Tambi Jarmi; Samir Khouzam; Nitika Shekhar; Meray Hosni; Launia White; David O Hodge; Martin L Mai; Hani M Wadei Journal: J Clin Med Res Date: 2020-12-18